Temple W J
Can J Surg. 1985 May;28(3):256-7, 261.
The most controversial aspect of breast disease centres around the management of patients who have either a strong family history of breast cancer or a biopsy diagnosis of lobular carcinoma in situ or ductal carcinoma in situ. The current alternatives for patients who have two or more relatives with breast cancer consist of close follow-up or prophylactic total mastectomies and reconstruction. Invasive breast cancer in patients with lobular carcinoma in situ may occur in either breast and may be as high as 30% at 20 to 30 years. In these women it is reasonable to do a wide excision of the lobular carcinoma; in those without a family history, close follow-up is adequate. Intraductal cancer treated by biopsy only is associated with a 40% risk of cancer in the ipsilateral breast. Therefore, the usual management is total mastectomy. However, the information to support this therapy over a segmental resection has limited scientific validity. Because the cosmetic appearance after total mastectomy and reconstruction is not as good as that of the normal breast, this procedure must be employed cautiously and only with the total support of the patient and her husband or close family. Subcutaneous mastectomy for prophylaxis leaves behind macroscopic glandular tissue and, therefore, is not considered by many to be optimal management. A total mastectomy, preserving the skin and resecting all macroscopic breast tissue and nipple, is the treatment of choice if the procedure is deemed appropriate.
乳腺疾病最具争议的方面集中在对那些有乳腺癌家族病史或经活检诊断为小叶原位癌或导管原位癌患者的治疗上。对于有两个或更多亲属患乳腺癌的患者,目前的选择包括密切随访或预防性全乳切除及乳房重建。小叶原位癌患者发生浸润性乳腺癌可能双侧乳房都出现,在20至30年时发生率可能高达30%。对于这些女性,对小叶原位癌进行广泛切除是合理的;对于那些没有家族病史的患者,密切随访就足够了。仅通过活检治疗的导管内癌,同侧乳房发生癌症的风险为40%。因此,通常的治疗方法是全乳切除。然而,支持这种治疗方法优于节段性切除的信息,其科学有效性有限。由于全乳切除及乳房重建后的外观不如正常乳房,这种手术必须谨慎采用,且必须得到患者及其丈夫或近亲的全力支持。预防性皮下乳房切除术会残留肉眼可见的腺体组织,因此,许多人认为这不是最佳治疗方法。如果认为该手术合适,保留皮肤并切除所有肉眼可见的乳腺组织和乳头的全乳切除术是首选治疗方法。